Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis
Per Soelberg Sørensen(University of Copenhagen), Massimo Filippi(Vita-Salute San Raffaele University), Steen Lisby(Genmab (Denmark)), Eva Havrdová(Charles University), Jelena Drulović(University of Belgrade), Frederick J. Derosier(GlaxoSmithKline (United Kingdom)), Steve Shackelford(GlaxoSmithKline (United Kingdom)), Richard Grove(GlaxoSmithKline (United Kingdom))
Cited by 276
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k